Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder

Neuropsychopharmacology. 2009 Sep;34(10):2265-74. doi: 10.1038/npp.2009.53. Epub 2009 Jun 3.

Abstract

Patients with bipolar disorder have abnormalities in glucocorticoid secretion, dopaminergic neurotransmission, and prefrontal cortical function. We hypothesized that the flattening of the diurnal glucocorticoid rhythm, commonly seen in bipolar disorder, modulates dopaminergic neurotransmission in the prefrontal cortex (PFC) leading to abnormalities in prefrontally mediated neurocognitive functions. To address this hypothesis, we investigated the effects of a flattened glucocorticoid rhythm on (i) the release of dopamine in the PFC and (ii) the transcription of genes in the ventral tegmental area (VTA) coding for proteins involved in presynaptic aspects of dopaminergic neurotransmission. Male rats were treated for 13-15 days with corticosterone (50 microg/ml in the drinking water) or vehicle (0.5% ethanol). Corticosterone treatment resulted in marked adrenal atrophy and flattening of the glucocorticoid rhythm as measured by repeated blood sampling. Animals treated with corticosterone showed markedly enhanced basal dopamine release in the PFC as measured by microdialysis in the presence of a dopamine reuptake inhibitor. Depolarization-evoked release was also enhanced, suggesting that the corticosterone effect on basal release did not result from an increase in the neuronal firing rate. Local blockade of terminal D(2) autoreceptors failed to normalize release to control values, suggesting that the enhanced release was not because of reduced autoreceptor sensitivity. In situ hybridization histochemistry showed that mRNAs coding tyrosine hydroxylase and the vesicular monoamine transporter 2 were elevated in the VTA of corticosterone-treated rats. Our data show that flattening of the glucocorticoid rhythm increases dopamine release in the PFC possibly as a result of increased synthesis and vesicular storage. This provides a mechanistic explanation for prefrontal dysfunction in bipolar and other affective disorders associated with glucocorticoid dysrhythmia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Glands / drug effects
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Body Weight / drug effects
  • Bupropion / pharmacology
  • Circadian Rhythm / drug effects*
  • Corticosterone / pharmacology*
  • Dopamine / metabolism*
  • Dopamine Antagonists / pharmacology
  • Dopamine Plasma Membrane Transport Proteins / genetics
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Dopamine Uptake Inhibitors / pharmacology
  • Drug Interactions
  • Gene Expression Regulation / drug effects
  • Male
  • Microdialysis / methods
  • Monoamine Oxidase / genetics
  • Monoamine Oxidase / metabolism
  • Potassium / pharmacology
  • Prefrontal Cortex / drug effects*
  • Prefrontal Cortex / metabolism
  • RNA, Messenger / metabolism
  • Rats
  • Receptors, Dopamine D2 / genetics
  • Receptors, Dopamine D2 / metabolism
  • Sulpiride / metabolism
  • Sulpiride / pharmacology
  • Synaptic Transmission / drug effects*
  • Time Factors
  • Tyrosine 3-Monooxygenase / genetics
  • Tyrosine 3-Monooxygenase / metabolism
  • Vesicular Monoamine Transport Proteins / genetics
  • Vesicular Monoamine Transport Proteins / metabolism

Substances

  • Anti-Inflammatory Agents
  • Dopamine Antagonists
  • Dopamine Plasma Membrane Transport Proteins
  • Dopamine Uptake Inhibitors
  • RNA, Messenger
  • Receptors, Dopamine D2
  • Slc18a2 protein, rat
  • Vesicular Monoamine Transport Proteins
  • Bupropion
  • Sulpiride
  • Tyrosine 3-Monooxygenase
  • Monoamine Oxidase
  • Potassium
  • Dopamine
  • Corticosterone